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Introduction & Objectives:	Imatinib mesylate is a tyrosine-kinase inhibitor used as the first-line 
treatment in chronic myeloid leukemia patients who are not candidate for allogeneic bone marrow 
transplantation. The most frequently reported drug-related side effects are edema, nausea, vomiting, 
muscle cramps, musculoskeletal pain, diarrhea and rash. 
Imatinib treatment is often associated with hypopigmentation, but only a few cases of 
mucocutaneous hyperpigmentation are described in literature. We are reporting an additional case 
of mucocutaneous blue hyperpigmentation in a patient affected by chronic myeloid leukemia and 
treated with imatinib since 2003. 
Material & Methods:	A review of the available literature regarding the hyperpigmentation related 
to imatinib was performed and one additional case was analysed. 
Results:	In our case imatinib therapy was well tolerated for several years and it led to an excellent 
hematological and cytogenetic response. However, the patient gradually developed an intense blue 
hyperpigmentation that involved the oral mucosa and part of the skin. Other causes of 
hyperpigmentation were excluded. 
Conclusions:	 Since 2001, when imatinib was approved from Food and Drug Administration for 
chronic myeloid leukemia, some cases of secondary hyperpigmentation were reported. This rare 
side effect should be recognized by the physicians. Moreover, the patient should be informed about 
this benign event before starting the therapy. Currently, no treatment is required for this condition 
and there is not indication to discontinue imatinib treatment. Further insight into the mechanisms of 
the pigmentary alterations caused by this drug is suggested for better treatment and prevention of 
these manifestations. 
